Henry Vanbrocklin, PhD

Professor
PROF IN RES-HCOMP

Biography

Henry VanBrocklin, PhD, is a Professor in Residence, Director of the Radiopharmaceutical Research Program in the Center for Molecular and Functional Imaging (CMFI) at the University of California, San Francisco China Basin, and he is a Joint Faculty Scientist at the Lawrence Berkeley National Laboratory. Dr. VanBrocklin obtained his PhD in Radiopharmaceutical Chemistry from Washington University, St. Louis in 1990, and he completed a two-year postdoctoral program at the University of Illinois, Urbana in 1992. He maintains an active radiotracer research program in addition to providing tracers for collaborative basic science and translational clinical research. His research interests include short-lived radioisotope production to the creation of fluorine-18 and carcbon-11 labeling chemistry strategies for new radiotracer preparations and applications.

Dr. VanBrocklin is one of the core faculty for the Master's in Biomedical Imaging (MSBI) program and a member of the MSBI executive committee.

Dr. VanBrocklin was awarded the Alexander Hollaender Distinguished Postdoctoral Fellowship from the U.S. Department of Energy for developing positron-labeled estrogens, progestins, and androgens for tumor imaging. He has 70 published research articles.

Expertise:
Radiopharmaceutical

Specialty:
Short-lived radioisotope production to the creation of fluorine-18 and carbon-11 labeling chemistry strategies for new radiotracer preparations and applications, development of positron-labeled estrogens, progestin’s, androgens for tumor imaging

Professional Interests:
Developing radiopharmaceutical probes for PET and SPECT imaging applications including tracers for blood flow measurement, receptor-targeted tracers for prostate, pancreatic and breast cancer, and neurological imaging agents for neuroinflammation and excititory amino acid transport.

Education and Training:
• Doctor of Philosophy: Washington University, St. Louis - Radiopharmaceutical Chemistry
• Postdoctoral Fellow: University of Illinois, Urbana

Honors and Awards

Editor-in-Chief, Molecular Imaging, 2011
SNM Presidents Distinguished Service Award, Society of Nuclear Medicine, 2010
SNM Presidents Distinguished Service Award, Society of Nuclear Medicine, 2006
Alexander Hollaender Distinguished Postdoctoral Fellow, US Department of Energy, 1990

Publications

Neumann KD, Villanueva-Meyer JE, Mutch CA, Flavell RR, Blecha JE, Kwak T, Sriram R, VanBrocklin HF, Rosenberg OS, Ohliger MA, Wilson DM. Imaging Active Infection in vivo Using D-Amino Acid Derived PET Radiotracers. Sci Rep. 2017 Aug 11; 7(1):7903.
Ronald JA, Kim BS, Gowrishankar G, Namavari M, Alam IS, D'Souza A, Nishikii H, Chuang HY, Ilovich O, Lin CF, Reeves R, Shuhendler A, Hoehne A, Chan CT, Baker J, Yaghoubi SS, VanBrocklin HF, Hawkins R, Franc BL, Jivan S, Slater JB, Verdin EF, Gao KT, Benjamin J, Negrin R, Gambhir SS. A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant. Cancer Res. 2017 Jun 01; 77(11):2893-2902.
Neumann KD, Thompson CM, Blecha JE, Gerdes JM, VanBrocklin HF. An improved radiosynthesis of O-(2-[18 F]fluoroethyl)-O-(p-nitrophenyl)methylphosphonate: A first-in-class cholinesterase PET tracer. J Labelled Comp Radiopharm. 2017 Jun 15; 60(7):337-342.
Blecha JE, Henderson BD, Hockley BG, VanBrocklin HF, Zubieta JK, DaSilva AF, Kilbourn MR, Koeppe RA, Scott PJH, Shao X. An updated synthesis of [11 C]carfentanil for positron emission tomography (PET) imaging of the µ-opioid receptor. J Labelled Comp Radiopharm. 2017 Jun 30; 60(8):375-380.
Korenchan DE, Taglang C, von Morze C, Blecha JE, Gordon JW, Sriram R, Larson PEZ, Vigneron DB, VanBrocklin HF, Kurhanewicz J, Wilson DM, Flavell RR. Dicarboxylic acids as pH sensors for hyperpolarized 13C magnetic resonance spectroscopic imaging. Analyst. 2017 May 02; 142(9):1429-1433.
Arentson-Lantz EJ, Saeed IH, Frassetto LA, Masharani U, Harnish RJ, Seo Y, VanBrocklin HF, Hawkins RA, Mari-Aparici C, Pampaloni MH, Slater J, Paddon-Jones D, Lang TF. 11C-L-methyl methionine dynamic PET/CT of skeletal muscle: response to protein supplementation compared to L-[ring 13C6] phenylalanine infusion with serial muscle biopsy. Ann Nucl Med. 2017 May; 31(4):295-303.
Franc BL, Goth S, MacKenzie J, Li X, Blecha J, Lam T, Jivan S, Hawkins RA, VanBrocklin H. In Vivo PET Imaging of the Activated Immune Environment in a Small Animal Model of Inflammatory Arthritis. Mol Imaging. 2017 Jan 01; 16:1536012117712638.
Kondapavulur S, Cote AM, Neumann KD, Jordan CD, McCoy D, Mabray MC, Liu D, Sze CH, Gautam A, VanBrocklin HF, Wilson M, Hetts SW. Optimization of an endovascular magnetic filter for maximized capture of magnetic nanoparticles. Biomed Microdevices. 2016 Dec; 18(6):109.
Dannoon S, Ganguly T, Cahaya H, Geruntho JJ, Galliher MS, Beyer SK, Choy CJ, Hopkins MR, Regan M, Blecha JE, Skultetyova L, Drake CR, Jivan S, Barinka C, Jones EF, Berkman CE, VanBrocklin HF. Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. J Med Chem. 2016 Jun 23; 59(12):5684-94.
Li L, Che L, Wang C, Blecha JE, Li X, VanBrocklin HF, Calvisi DF, Puchowicz M, Chen X, Seo Y. [(11)C]acetate PET Imaging is not Always Associated with Increased Lipogenesis in Hepatocellular Carcinoma in Mice. Mol Imaging Biol. 2016 Jun; 18(3):360-7.
Schankin CJ, Maniyar FH, Seo Y, Kori S, Eller M, Chou DE, Blecha J, Murphy ST, Hawkins RA, Sprenger T, VanBrocklin HF, Goadsby PJ. Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. Brain. 2016 Jul; 139(Pt 7):1994-2001.
Drake CR, Sevillano N, Truillet C, Craik CS, VanBrocklin HF, Evans MJ. Site-Specific Radiofluorination of Biomolecules with 8-[(18)F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase. ACS Chem Biol. 2016 06 17; 11(6):1587-94.
Carroll VN, Truillet C, Shen B, Flavell RR, Shao X, Evans MJ, VanBrocklin HF, Scott PJ, Chin FT, Wilson DM. [(11)C]Ascorbic and [(11)C]dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography. Chem Commun (Camb). 2016 Apr 07; 52(27):4888-90.
Korenchan DE, Flavell RR, Baligand C, Sriram R, Neumann K, Sukumar S, VanBrocklin H, Vigneron DB, Wilson DM, Kurhanewicz J. Dynamic nuclear polarization of biocompatible (13)C-enriched carbonates for in vivo pH imaging. Chem Commun (Camb). 2016 Feb 18; 52(14):3030-3.
Flavell RR, Truillet C, Regan MK, Ganguly T, Blecha JE, Kurhanewicz J, VanBrocklin HF, Keshari KR, Chang CJ, Evans MJ, Wilson DM. Caged [(18)F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography. Bioconjug Chem. 2016 Jan 20; 27(1):170-8.
Page MJ, Lourenço AL, David T, LeBeau AM, Cattaruzza F, Castro HC, VanBrocklin HF, Coughlin SR, Craik CS. Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography. Nat Commun. 2015 Oct 01; 6:8448.
Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015 Aug; 40(6):1432-40.
Keshari KR, Wilson DM, Van Criekinge M, Sriram R, Koelsch BL, Wang ZJ, VanBrocklin HF, Peehl DM, O'Brien T, Sampath D, Carano RA, Kurhanewicz J. Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor. Prostate. 2015 Oct; 75(14):1601-9.
Ganguly T, Dannoon S, Hopkins MR, Murphy S, Cahaya H, Blecha JE, Jivan S, Drake CR, Barinka C, Jones EF, VanBrocklin HF, Berkman CE. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Nucl Med Biol. 2015 Oct; 42(10):780-7.
Hope TA, Aggarwal R, Simko JP, VanBrocklin HF, Ryan CJ. Somatostatin imaging of neuroendocrine-differentiated prostate cancer. Clin Nucl Med. 2015 Jun; 40(6):540-1.
Ley CR, Beattie NR, Dannoon S, Regan M, VanBrocklin H, Berkman CE. Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen. Bioorg Med Chem Lett. 2015 Jun 15; 25(12):2536-9.
LeBeau AM, Sevillano N, Markham K, Winter MB, Murphy ST, Hostetter DR, West J, Lowman H, Craik CS, VanBrocklin HF. Imaging active urokinase plasminogen activator in prostate cancer. Cancer Res. 2015 Apr 01; 75(7):1225-35.
Carroll V, Michel BW, Blecha J, VanBrocklin H, Keshari K, Wilson D, Chang CJ. A boronate-caged [¹8F]FLT probe for hydrogen peroxide detection using positron emission tomography. J Am Chem Soc. 2014 Oct 22; 136(42):14742-5.
Schwarz SW, Dick D, VanBrocklin HF, Hoffman JM. Regulatory Requirements for PET Drug Production. J Nucl Med. 2014 Jul; 55(7):1132-7.
James SL, Ahmed SK, Murphy S, Braden MR, Belabassi Y, VanBrocklin HF, Thompson CM, Gerdes JM. A novel fluorine-18 ß-fluoroethoxy organophosphate positron emission tomography imaging tracer targeted to central nervous system acetylcholinesterase. ACS Chem Neurosci. 2014 Jul 16; 5(7):519-24.
LeBeau AM, Sevillano N, King ML, Duriseti S, Murphy ST, Craik CS, Murphy LL, VanBrocklin HF. Imaging the urokinase plasminongen activator receptor in preclinical breast cancer models of acquired drug resistance. Theranostics. 2014; 4(3):267-79.
Nordstrom R, Cherry S, Azhdarinia A, Sevick-Muraca E, Vanbrocklin H. Photons across medicine: relating optical and nuclear imaging. Biomed Opt Express. 2013; 4(12):2751-62.
Keshari KR, Sai V, Wang ZJ, Vanbrocklin HF, Kurhanewicz J, Wilson DM. Hyperpolarized [1-13C]dehydroascorbate MR spectroscopy in a murine model of prostate cancer: comparison with 18F-FDG PET. J Nucl Med. 2013 Jun; 54(6):922-8.
LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, Craik CS. Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res. 2013 Apr 01; 73(7):2070-81.
LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, VanBrocklin HF, Craik CS. Imaging a functional tumorigenic biomarker in the transformed epithelium. Proc Natl Acad Sci U S A. 2013 Jan 02; 110(1):93-8.
Seo Y, Gustafson WC, Dannoon SF, Nekritz EA, Lee CL, Murphy ST, VanBrocklin HF, Hernandez-Pampaloni M, Haas-Kogan DA, Weiss WA, Matthay KK. Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol Imaging Biol. 2012 Dec; 14(6):735-42.
Vaquero JJ, Gao DW, García-Villaba C, Bacharach S, Vanbrocklin H, Fang Q, Desco M, Lee R, Dae M. Approach to assessing myocardial perfusion in rats using static [13N]-ammonia images and a small-animal PET. Mol Imaging Biol. 2012 Oct; 14(5):541-5.
McCarthy TJ, Vanbrocklin HF. In memoriam: Michael John Welch, Ph.D 1939-2012. Mol Imaging Biol. 2012 Aug; 14(4):393-4.
Wilson KJ, Mill CP, Gallo RM, Cameron EM, VanBrocklin H, Settleman J, Riese DJ. The Q43L mutant of neuregulin 2ß is a pan-ErbB receptor antagonist. Biochem J. 2012 Apr 01; 443(1):133-44.
VanBrocklin H. Accepting the torch. Mol Imaging. 2012 Feb; 11(1):1.
Broisat A, Ruiz M, Goodman NC, Hanrahan SM, Reutter BW, Brennan KM, Janabi M, Schaefer S, Watson DD, Beller GA, VanBrocklin HF, Glover DK. Myocardial uptake of 7'-(Z)-[(123)I]iodorotenone during vasodilator stress in dogs with critical coronary stenoses. Circ Cardiovasc Imaging. 2011 Nov; 4(6):685-92.
Norenberg JP, Schwarz S, VanBrocklin H. FDA cGMP requirements for PET drugs. J Nucl Med. 2011 May; 52(5):16N.
Iyer AK, Lan X, Zhu X, Su Y, Feng J, Zhang X, Gao D, Seo Y, Vanbrocklin HF, Broaddus VC, Liu B, He J. Novel human single chain antibody fragments that are rapidly internalizing effectively target epithelioid and sarcomatoid mesotheliomas. Cancer Res. 2011 Apr 01; 71(7):2428-32.
Vasdev N, Dorff PN, O'Neil JP, Chin FT, Hanrahan S, VanBrocklin HF. Metabolic stability of 6,7-dialkoxy-4-(2-, 3- and 4-[18F]fluoroanilino)quinazolines, potential EGFR imaging probes. Bioorg Med Chem. 2011 May 01; 19(9):2959-65.
More SS, Itsara M, Yang X, Geier EG, Tadano MK, Seo Y, Vanbrocklin HF, Weiss WA, Mueller S, Haas-Kogan DA, Dubois SG, Matthay KK, Giacomini KM. Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res. 2011 Apr 15; 17(8):2339-49.
Iyer AK, Su Y, Feng J, Lan X, Zhu X, Liu Y, Gao D, Seo Y, Vanbrocklin HF, Courtney Broaddus V, Liu B, He J. The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma. Biomaterials. 2011 Apr; 32(10):2605-13.
Vanbrocklin H, Schwarz S. CGMP for PET drugs: important steps to take now. J Nucl Med. 2010 Dec; 51(12):17N.
Hicks JW, VanBrocklin HF, Wilson AA, Houle S, Vasdev N. Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT. Molecules. 2010 Nov 15; 15(11):8260-78.
Lee CL, Wahnishe H, Sayre GA, Cho HM, Kim HJ, Hernandez-Pampaloni M, Hawkins RA, Dannoon SF, VanBrocklin HF, Itsara M, Weiss WA, Yang X, Haas-Kogan DA, Matthay KK, Seo Y. Radiation dose estimation using preclinical imaging with I124-metaiodobenzylguanidine (MIBG) PET. Med Phys. 2010 Sep; 37(9):4861-4867.
Lee CL, Wahnishe H, Sayre GA, Cho HM, Kim HJ, Hernandez-Pampaloni M, Hawkins RA, Dannoon SF, VanBrocklin HF, Itsara M, Weiss WA, Yang X, Haas-Kogan DA, Matthay KK, Seo Y. Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys. 2010 Sep; 37(9):4861-7.
Mihardja SS, Gao D, Sievers RE, Fang Q, Feng J, Wang J, Vanbrocklin HF, Larrick JW, Huang M, Dae M, Lee RJ. Targeted in vivo extracellular matrix formation promotes neovascularization in a rodent model of myocardial infarction. PLoS One. 2010 Apr 28; 5(4):e10384.
Anderson CJ, Bulte JW, Chen K, Chen X, Khaw BA, Shokeen M, Wooley KL, VanBrocklin HF. Design of targeted cardiovascular molecular imaging probes. J Nucl Med. 2010 May 01; 51 Suppl 1:3S-17S.
He J, Wang Y, Feng J, Zhu X, Lan X, Iyer AK, Zhang N, Seo Y, VanBrocklin HF, Liu B. Targeting prostate cancer cells in vivo using a rapidly internalizing novel human single-chain antibody fragment. J Nucl Med. 2010 Mar; 51(3):427-32.
Lapi SE, Wahnishe H, Pham D, Wu LY, Nedrow-Byers JR, Liu T, Vejdani K, VanBrocklin HF, Berkman CE, Jones EF. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med. 2009 Dec; 50(12):2042-8.
Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, VanBrocklin HF, Wright JF, Bankiewicz KS, Aminoff MJ. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology. 2009 Nov 17; 73(20):1662-9.
VanBrocklin HF. Introduction to special issue. Mol Imaging. 2009 Mar-Apr; 8(2):55.
Watkins GA, Jones EF, Scott Shell M, VanBrocklin HF, Pan MH, Hanrahan SM, Feng JJ, He J, Sounni NE, Dill KA, Contag CH, Coussens LM, Franc BL. Development of an optimized activatable MMP-14 targeted SPECT imaging probe. Bioorg Med Chem. 2009 Jan 15; 17(2):653-9.
VanBrocklin HF. Advancing molecular imaging from the laboratory to everyday practice. J Nucl Med. 2008 Dec; 49(12):22N-23N.
Jones EF, Gould RG, VanBrocklin HF. Bruce H. Hasegawa, PhD, 1951-2008. J Nucl Med. 2008 Sep; 49(9):37N-38N.
VanBrocklin H. Session 2: strategies for fast-track technological development and regulatory issues. J Nucl Med. 2008 Jun; 49(6):38N-39N.
VanBrocklin H, Herscovitch P. Molecular imaging update: advances in MI of the brain. J Nucl Med. 2007 May; 48(5):24N, 29N.
VanBrocklin HF, Hanrahan SM, Enas JD, Nandanan E, O'Neil JP. Mitochondrial avid radioprobes. Preparation and evaluation of 7'(Z)-[125I]iodorotenone and 7'(Z)-[125I]iodorotenol. Nucl Med Biol. 2007 Jan; 34(1):109-16.
VanBrocklin HF, Lim JK, Coffing SL, Hom DL, Negash K, Ono MY, Gilmore JL, Bryant I, Riese DJ. Anilinodialkoxyquinazolines: screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. J Med Chem. 2005 Nov 17; 48(23):7445-56.
VanBrocklin HF, Blagoev M, Hoepping A, O'Neil JP, Klose M, Schubiger PA, Ametamey S. A new precursor for the preparation of 6-[18F]Fluoro-L-m-tyrosine ([18F]FMT): efficient synthesis and comparison of radiolabeling. Appl Radiat Isot. 2004 Dec; 61(6):1289-94.
Marshall RC, Powers-Risius P, Reutter BW, O'Neil JP, La Belle M, Huesman RH, VanBrocklin HF. Kinetic analysis of 18F-fluorodihydrorotenone as a deposited myocardial flow tracer: comparison to 201Tl. J Nucl Med. 2004 Nov; 45(11):1950-9.
Hung JC, VanBrocklin HF. Exemption of radiopharmaceuticals from <797>. J Nucl Med. 2004 Oct; 45(10):14N.
Eberling JL, Roberts JA, Taylor SE, VanBrocklin HF, O'Neil JP, Nordahl TE. No effect of age and estrogen on aromatic L- amino acid decarboxylase activity in rhesus monkey brain. Neurobiol Aging. 2002 May-Jun; 23(3):479-83.
Collier TL, Lecomte R, McCarthy TJ, Meikle S, Ruth TJ, Scopinaro F, Signore A, VanBrocklin H, van De Wiele C, Waterhouse RN. Assessment of cancer-associated biomarkers by positron emission tomography: advances and challenges. Dis Markers. 2002; 18(5-6):211-47.
Marshall RC, Powers-Risius P, Reutter BW, Taylor SE, VanBrocklin HF, Huesman RH, Budinger TF. Kinetic analysis of 125I-iodorotenone as a deposited myocardial flow tracer: comparison with 99mTc-sestamibi. J Nucl Med. 2001 Feb; 42(2):272-81.
Eberling JL, Jagust WJ, Taylor S, Bringas J, Pivirotto P, VanBrocklin HF, Bankiewicz KS. A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes. Brain Res. 1998 Sep 14; 805(1-2):259-62.
Jordan S, Bankiewicz KS, Eberling JL, VanBrocklin HF, O'Neil JP, Jagust WJ. An in vivo microdialysis study of striatal 6-[18F]fluoro-L-m-tyrosine metabolism. Neurochem Res. 1998 Apr; 23(4):513-7.
Eberling JL, Bankiewicz KS, Jordan S, VanBrocklin HF, Jagust WJ. PET studies of functional compensation in a primate model of Parkinson's disease. Neuroreport. 1997 Aug 18; 8(12):2727-33.
Jordan S, Eberling JL, Bankiewicz KS, Rosenberg D, Coxson PG, VanBrocklin HF, O'Neil JP, Emborg ME, Jagust WJ. 6-[18F]fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates. Brain Res. 1997 Mar 07; 750(1-2):264-76.
Jagust WJ, Eberling JL, Biegon A, Taylor SE, VanBrocklin HF, Jordan S, Hanrahan SM, Roberts JA, Brennan KM, Mathis CA. Iodine-123-5-iodo-6-nitroquipazine: SPECT radiotracer to image the serotonin transporter. J Nucl Med. 1996 Jul; 37(7):1207-14.
Eberling JL, Roberts JA, De Manincor DJ, Brennan KM, Hanrahan SM, Vanbrocklin HF, Roos MS, Jagust WJ. PET studies of cerebral glucose metabolism in conscious rhesus macaques. Neurobiol Aging. 1995 Sep-Oct; 16(5):825-32.
Buckman BO, VanBrocklin HF, Dence CS, Bergmann SR, Welch MJ, Katzenellenbogen JA. Synthesis and tissue biodistribution of [omega-11C]palmitic acid. A novel PET imaging agent for cardiac fatty acid metabolism. J Med Chem. 1994 Jul 22; 37(15):2481-5.
VanBrocklin HF, Liu A, Welch MJ, O'Neil JP, Katzenellenbogen JA. The synthesis of 7 alpha-methyl-substituted estrogens labeled with fluorine-18: potential breast tumor imaging agents. Steroids. 1994 Jan; 59(1):34-45.
Jagust WJ, Eberling JL, Roberts JA, Brennan KM, Hanrahan SM, VanBrocklin H, Enas JD, Biegon A, Mathis CA. In vivo imaging of the 5-hydroxytryptamine reuptake site in primate brain using single photon emission computed tomography and [123I]5-iodo-6-nitroquipazine. Eur J Pharmacol. 1993 Sep 28; 242(2):189-93.
Katzenellenbogen JA, Mathias CJ, VanBrocklin HF, Brodack JW, Welch MJ. Titration of the in vivo uptake of 16 alpha-[18F]fluoroestradiol by target tissues in the rat: competition by tamoxifen, and implications for quantitating estrogen receptors in vivo and the use of animal models in receptor-binding radiopharmaceutical development. Nucl Med Biol. 1993 Aug; 20(6):735-45.
VanBrocklin HF, Carlson KE, Katzenellenbogen JA, Welch MJ. 16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors. J Med Chem. 1993 May 28; 36(11):1619-29.
Kochanny MJ, VanBrocklin HF, Kym PR, Carlson KE, O'Neil JP, Bonasera TA, Welch MJ, Katzenellenbogen JA. Fluorine-18-labeled progestin ketals: synthesis and target tissue uptake selectivity of potential imaging agents for receptor-positive breast tumors. J Med Chem. 1993 Apr 30; 36(9):1120-7.
VanBrocklin HF, Rocque PA, Lee HV, Carlson KE, Katzenellenbogen JA, Welch MJ. 16 beta-[18F]fluoromoxestrol: a potent, metabolically stable positron emission tomography imaging agent for estrogen receptor positive human breast tumors. Life Sci. 1993; 53(10):811-9.
French AN, Napolitano E, VanBrocklin HF, Hanson RN, Welch MJ, Katzenellenbogen JA. Synthesis, radiolabeling and tissue distribution of 11 beta-fluoroalkyl- and 11 beta-fluoroalkoxy-substituted estrogens: target tissue uptake selectivity and defluorination of a homologous series of fluorine-18-labeled estrogens. Nucl Med Biol. 1993 Jan; 20(1):31-47.
Pomper MG, Kochanny MJ, Thieme AM, Carlson KE, VanBrocklin HF, Mathias CJ, Welch MJ, Katzenellenbogen JA. Fluorine-substituted corticosteroids: synthesis and evaluation as potential receptor-based imaging agents for positron emission tomography of the brain. Int J Rad Appl Instrum B. 1992 May; 19(4):461-80.
VanBrocklin HF, Pomper MG, Carlson KE, Welch MJ, Katzenellenbogen JA. Preparation and evaluation of 17-ethynyl-substituted 16 alpha-[18F]fluoroestradiols: selective receptor-based PET imaging agents. Int J Rad Appl Instrum B. 1992 Apr; 19(3):363-74.
Liu AJ, Katzenellenbogen JA, VanBrocklin HF, Mathias CJ, Welch MJ. 20-[18F]fluoromibolerone, a positron-emitting radiotracer for androgen receptors: synthesis and tissue distribution studies. J Nucl Med. 1991 Jan; 32(1):81-8.
Pomper MG, VanBrocklin H, Thieme AM, Thomas RD, Kiesewetter DO, Carlson KE, Mathias CJ, Welch MJ, Katzenellenbogen JA. 11 beta-methoxy-, 11 beta-ethyl- and 17 alpha-ethynyl-substituted 16 alpha-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity. J Med Chem. 1990 Dec; 33(12):3143-55.
Pochapsky SS, VanBrocklin HF, Welch MJ, Katzenellenbogen JA. Synthesis and tissue distribution of fluorine-18 labeled trifluorohexadecanoic acids. Considerations in the development of metabolically blocked myocardial imaging agents. Bioconjug Chem. 1990 Jul-Aug; 1(4):231-44.
VanBrocklin HF, Brodack JW, Mathias CJ, Welch MJ, Katzenellenbogen JA, Keenan JF, Mizejewski GJ. Binding of 16 alpha-[18F]fluoro-17 beta-estradiol to alphafetoprotein in Sprague-Dawley female rats affects blood levels. Int J Rad Appl Instrum B. 1990; 17(8):769-73.